Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV vaccine candidate (five-antigen)
- Development stage
- Unknown
- Lead developer
- Vaccine Industrial Company
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The EBV vaccine candidate (five-antigen) is a preclinical-stage prophylactic and therapeutic vaccine developed by The Vaccine Company (acquired by Eli Lilly). It utilizes a proprietary In Vivo Nanoparticle (IVN) platform that combines mRNA technology with the ability to form virus-like particles (VLPs) directly within the recipient's body. The vaccine is designed to express five distinct Epstein-Barr virus (EBV) antigens to elicit a broad and comprehensive immune response. Its primary indications include the prevention of infectious mononucleosis and potential applications in treating or preventing EBV-associated conditions such as multiple sclerosis (MS) and various EBV-associated malignancies, including lymphomas and nasopharyngeal carcinoma.
- Other names
- Five-antigen EBV vaccine candidateEBV vaccine candidate (five-antigen)
02
Targets
Epstein-Barr virus entry and structural glycoproteins (gp350, gB, gH, gL, gp42)
Beyond the preview
Go deeper on EBV vaccine candidate (five-antigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV vaccine candidate (five-antigen).